Combining high-throughput single B-cell screening with artificial intelligence is changing how quickly and how reliably antibody developers can move from immunization to a validated lead. Single B-cell screening (SBC) captures native heavy- and light-chain pairing directly from individual B cells, while AI models layered on top prioritize which of those recovered sequences merit synthesis and wet lab testing. Together, the two approaches compress a process that has historically relied on slow, low-yield funneling into a faster, data-driven workflow. The following questions address how this combination works in practice, where it outperforms conventional methods, and where its limits still require human scientific judgment.
What is high-throughput single B-cell screening, and why does it matter for antibody discovery?
High-throughput single B-cell screening (SBC) isolates individual antibody-producing B cells and recovers their natively paired heavy- and light-chain sequences, rather than sequencing bulk populations of cells. This preserves the original chain pairing that occurred during the immune response, which matters because pairing is what determines a functional, correctly folded antibody. Though SBC could retrieve fewer sequences than NGS, its sequences could cover the majority of the diversity from NGS. SBC could also yield some unique clusters that could not be identified by NGS. That combination of native pairing and diversity coverage is why SBC has become a preferred entry point for high-quality lead generation.
How does single B-cell screening compare to next-generation sequencing (NGS) in practical yield?
Single B-cell screening delivers a dramatically higher positive rate for recombinant antibodies than bulk NGS-based approaches. Considering the much better recovery rate of SBC (greater than 70% positive rate for recombinant antibodies from SBC screening, generally less than 10% positive rate for NGS), the screening efficiency would be much better. In practice, this means fewer sequences need to be synthesized and tested to find a working binder, which shortens the time spent in the recombinant expression and binding-confirmation stages of a program.
|
Metric |
Single B-Cell Screening (SBC) |
Next-Generation Sequencing (NGS) |
|---|---|---|
|
Positive rate for recombinant antibodies |
Greater than 70% |
Generally less than 10% |
|
Chain pairing |
Native, preserved from source cell |
Requires computational or combinatorial pairing |
|
Sequence diversity captured |
Covers majority of NGS diversity, plus unique clusters |
Broadest raw diversity |
|
Screening efficiency |
High |
Lower per-sequence hit rate |
Where does high-throughput screening on Claudin 18.2 illustrate this positivity rate in a real program?
Positivity rates well above industry norms have been demonstrated in HCAb (heavy-chain-only antibody) discovery campaigns run against solid tumor targets. In a Claudin 18.2 program, high-throughput transfections of HEK293 cells and high-throughput production of the antibodies into the supernatant were followed by testing binding for Claudin 18.2-specific binding, with a positivity rate at a minimum of 60% and up to 80% in some plates, compared to standard screening methods. From the resulting positive HCAb pool, 24 antibodies were selected and evaluated for binding to Claudin 18.2, showing no signal on CHO controls and excellent binding to Claudin 18.2. Notably, four of these HCAbs also showed binding to Claudin 18.1, underscoring the ability to identify at least multiple epitopes at a relatively high rate from this screening platform.
How does AI actually get integrated into the discovery workflow, and how is that different from a CRO simply “using AI” as a tool?
Most organizations that claim to “use AI” apply it as a bolt-on analysis step at a single stage of discovery. Nona Biosciences instead embeds AI across the full discovery pathway rather than at one checkpoint. Nona adopts an end-to-end AI integration strategy where AI is embedded in every step of the antibody discovery workflow, from target validation all the way to antibody engineering and CMC. In this process, AI models take the wheel to generate novel sequences and determine which variants are prioritized in wet lab validation, and Nona operates a data flywheel to actively generate, collect, and curate data to fine-tune proprietary AI models and generate better molecules in an iterative manner. This is a structural difference from applying AI as a post-hoc filter on data generated by unrelated processes.
At what point in a program does AI developability scoring make the biggest difference?
AI developability scoring has its greatest impact during early lead triage, when a program decides which subset of binders advances to synthesis and testing. AI developability scoring is applicable in various stages where the decision of which molecules should survive to the next step matters, and in particular, during early lead triage, choosing the right subset of binders to be further synthesized and tested is of great importance to advance a diverse set of sequences that exhibit no developability or manufacturability risks. Applying this scoring early, rather than late in the funnel, is what prevents developability liabilities from surviving into resource-intensive stages of a program.
Can AI-based developability scoring actually prevent late-stage failures that traditional screening would miss?
Yes. Conventional, sequential screening assesses developability and manufacturability attributes step by step, which means potent candidates often are not flagged as problematic until much later in the process. Traditional screening is a funneled process where developability and manufacturability attributes are assessed step by step, and it is common to encounter potent candidates that are found to have low yield because of poor folding or aggregation. These defects and risks can be effectively identified at the very beginning with AI-based developability assessment and subsequently avoided to improve the success rate of discovery campaigns. This early-warning function is one of the clearest practical benefits of pairing computational scoring with high-throughput screening output.
Where does Hu-mAtrIx™ fit into this workflow, and what does it add beyond raw screening throughput?
Nona Biosciences’ Hu-mAtrIx™ AI platform integrated in discovery extends the SBC and NGS output further by guiding the incorporation of developability-optimized sequences, rather than relying on affinity and epitope data alone to rank candidates. This layered approach reflects a broader industry shift: the market is moving toward high-throughput single B cell screening and next-generation sequencing (NGS) integrated with in vivo technologies, and pairing that throughput with computational developability scoring is what converts raw screening volume into a shortlist of manufacturable candidates.
Where does AI in antibody discovery still fall short, and where is human judgment still required?
Data scarcity is the key limiting factor for applying AI in antibody discovery, and novel drug development is a high-risk process where human scientists have to make judgment calls based on multi-dimensional information, not only trade-offs on the antibodies but also on the target biology, the experimental reality, and the competitor landscape. AI models are trained on very limited and incomplete data from historical programs, and it is extremely difficult to generalize to new situations such as novel targets or new modalities. This is why AI functions as a prioritization and risk-flagging layer within Nona’s discovery process, not a replacement for experienced scientific review.
Is “high-throughput single B-cell screening” the same thing as “next-generation sequencing,” and why does the distinction matter for buyers?
No, these are frequently confused but mechanically distinct approaches. NGS sequences bulk populations of cells and infers or computationally reconstructs chain pairing, whereas single B-cell screening isolates individual cells and captures native heavy- and light-chain pairs directly, without reconstruction. Buyers evaluating discovery partners should ask specifically whether native pairing is preserved end to end, since SBC covers the majority of NGS diversity and yields unique clusters NGS cannot identify, while carrying a substantially different positivity profile at the recombinant expression stage. Understanding the technical nuances of single B-cell screening vs. hybridoma methods is also critical for selecting the right platform for specific therapeutic goals.
When should a discovery program prioritize combined SBC-plus-AI screening over a conventional hybridoma or bulk sequencing approach?
Programs facing tight timelines, complex targets with multiple epitope requirements, or early signs of developability risk benefit most from combining single B-cell screening with AI-driven triage. Conventional hybridoma methods and bulk NGS workflows can surface candidates, but they typically defer developability assessment to later funnel stages, increasing the chance of late attrition. A program targeting a difficult antigen, needing multi-epitope coverage, or requiring fully human HCAbs from Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies) for downstream bispecific or CAR-based formats is well suited to this combined approach, since native pairing plus early AI scoring reduces rework before candidates reach engineering and CMC. Developers exploring this route can review Nona’s approach to single B-cell screening through its Beacon® (single B-cell screening instrument used for high-recovery HCAb isolation) platform, and pair it with functional screening capabilities described on Nona’s antibody engineering page. For those looking to outsource these complex workflows, learning how to select an integrated antibody discovery CRO can ensure the partner has the necessary computational and wet-lab infrastructure.
Partnering with Nona offers direct access to a discovery workflow where high-recovery single B-cell screening and end-to-end AI integration operate together rather than as separate, sequential steps. Developers evaluating antibody discovery partners can explore Nona Biosciences’ Beacon® single B-cell screening platform and the Hu-mAtrIx™ AI platform to see how native chain pairing and developability-optimized sequence selection combine to reduce late-stage attrition and accelerate lead generation.
-
Wang B. et al., Facile discovery of a diverse panel of anti-Ebola virus antibodies by immune repertoire mining, Scientific Reports, 2015. Link
-
DeKosky B.J. et al., High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire, Nature Biotechnology, 2013. Link
-
Tiller T. et al., Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning, Journal of Immunological Methods, 2008. Link
-
Setliff I. et al., High-throughput mapping of B cell receptor sequences to antigen specificity, Cell, 2019. Link
-
Norman R.A. et al., Computational approaches to therapeutic antibody design: established methods and emerging trends, Briefings in Bioinformatics, 2020. Link
-
Raybould M.I.J. et al., Five computational developability guidelines for therapeutic antibody profiling, PNAS, 2019. Link
-
Jain T. et al., Biophysical properties of the clinical-stage antibody landscape, PNAS, 2017. Link
